Oncotelic Therapeutics Partners with TechForce Robotics for GMP Robotics Platform

The companies will commercialize Oncotelic's PDAOAI-enhanced robotic manufacturing technology.

Apr. 2, 2026 at 3:31pm

Got story updates? Submit your updates here. ›

Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, has announced a strategic partnership with TechForce Robotics to commercialize Oncotelic's PDAOAI-enhanced GMP (Good Manufacturing Practice) robotics platform. The partnership aims to leverage Oncotelic's proprietary technology to advance automated, high-quality pharmaceutical manufacturing.

Why it matters

The collaboration between Oncotelic and TechForce Robotics represents an important step in the integration of advanced robotics and automation into the pharmaceutical industry. By enhancing GMP manufacturing with Oncotelic's PDAOAI technology, the partnership could lead to more efficient, consistent, and cost-effective drug production.

The details

Oncotelic's PDAOAI (Programmed Death-Associated Oligoadenylate Synthetase Activating Immunotherapy) technology is designed to improve the quality and consistency of GMP manufacturing processes. TechForce Robotics, a leader in robotic automation solutions, will work with Oncotelic to commercialize this enhanced robotics platform for pharmaceutical applications.

  • The partnership was announced on April 2, 2026.

The players

Oncotelic Therapeutics, Inc.

A clinical-stage biopharmaceutical company that develops therapies for cancer and other life-threatening disorders.

TechForce Robotics

A company that specializes in robotic automation solutions for various industries, including the pharmaceutical sector.

Got photos? Submit your photos here. ›

The takeaway

This partnership between Oncotelic and TechForce Robotics represents a significant advancement in the integration of advanced robotics and automation into the pharmaceutical industry, which could lead to more efficient, consistent, and cost-effective drug production.